OncoMatch/Clinical Trials/NCT04755920
SGM-101 in Colorectal Brain Metastases.
Is NCT04755920 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies SGM-101 for rectal neoplasms.
Treatment: SGM-101 — This study assesses the feasibility of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen monoclonal antibody, for intraoperative near-infrared fluorescence imaging of colorectal brain metastases by injecting SGM-101 intravenously 3 - 5 days prior to surgery.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Glioblastoma
Gastric Cancer
Hepatocellular Carcinoma
Pancreatic Cancer
Cholangiocarcinoma
Esophageal Carcinoma
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: SGM-101 (SGM-101)
Previous use of SGM-101
Lab requirements
Blood counts
Platelet count below 100 x 10^9/L; Hemoglobin below 4 mmol/L (females) or below 5 mmol/L (males)
Kidney function
Serum creatinine above 1.5 times the ULN
Liver function
Aspartate AminoTransferase, Alanine AminoTransferase, Gamma Glutamyl Transferase or Alkaline Phosphatase levels above 5 times the [ULN]; Total bilirubin above 2 times the ULN
Laboratory abnormalities defined as: Aspartate AminoTransferase, Alanine AminoTransferase, Gamma Glutamyl Transferase or Alkaline Phosphatase levels above 5 times the [ULN]; Total bilirubin above 2 times the ULN; Serum creatinine above 1.5 times the ULN; Platelet count below 100 x 10^9/L; Hemoglobin below 4 mmol/L (females) or below 5 mmol/L (males)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify